Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. daily Stock Chart
Gilead Sciences, Inc.
IndexS&P 500 P/E7.53 EPS (ttm)9.46 Insider Own0.40% Shs Outstand1.31B Perf Week9.90%
Market Cap93.18B Forward P/E9.39 EPS next Y7.59 Insider Trans-8.49% Shs Float1.30B Perf Month10.35%
Income12.64B PEG- EPS next Q2.11 Inst Own76.90% Short Float0.83% Perf Quarter5.54%
Sales29.10B P/S3.20 EPS this Y-16.50% Inst Trans-1.41% Short Ratio1.29 Perf Half Y-2.81%
Book/sh15.63 P/B4.56 EPS next Y-9.11% ROA22.80% Target Price77.66 Perf Year-11.47%
Cash/sh10.79 P/C6.60 EPS next 5Y-5.60% ROE70.50% 52W Range63.76 - 88.85 Perf YTD-0.52%
Dividend2.08 P/FCF10.27 EPS past 5Y41.20% ROI31.00% 52W High-19.82% Beta1.23
Dividend %2.92% Quick Ratio2.40 Sales past 5Y29.40% Gross Margin86.20% 52W Low11.73% ATR1.26
Employees9000 Current Ratio2.60 Sales Q/Q-16.50% Oper. Margin57.60% RSI (14)76.04 Volatility2.91% 1.75%
OptionableYes Debt/Eq1.29 EPS Q/Q-18.90% Profit Margin43.40% Rel Volume1.68 Prev Close70.52
ShortableYes LT Debt/Eq1.29 EarningsAug 01 AMC Payout20.20% Avg Volume8.34M Price71.24
Recom2.30 SMA208.70% SMA507.79% SMA2000.13% Volume14,017,979 Change1.02%
Jun-23-17Initiated Deutsche Bank Buy $79
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Jun-26-17 08:15AM  Featured Company News - Gilead's Vosevi Receives Positive Opinion from European CHMP; Set to Deliver Advanced Treatment for All HCV Genotypes Accesswire
Jun-24-17 04:03PM  Barron's Picks And Pans: Canadian Stocks, NCR, Gilead And More Benzinga
08:33AM  2 Top Biotech Stocks to Buy on Sale Motley Fool
Jun-23-17 05:00PM  These stocks are trading at extremes CNBC Videos
05:00PM  8 ways to trade this week's extreme movers CNBC Videos
04:15PM  Is Gilead Sciences on the Verge of a Powerful Rally?
04:10PM  [$$] Gilead Is Finally a Buy: 'Value Trap No More'
12:57PM  Gilead: The Worst is Over?
12:14PM  Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout
09:54AM  Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold Benzinga
07:35AM  European CHMP Adopts Positive Opinion for Gileads Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes Business Wire
Jun-22-17 04:50PM  Biotech Resurgence Has Bite But No FAANGs Forbes
04:05PM  Why The Biotech Rally Could Still Tack On Another 15% Upside Investor's Business Daily
12:51PM  Go, Gilead, Go!
08:15AM  Gilead Sciences, Inc. breached its 50 day moving average in a Bullish Manner : GILD-US : June 22, 2017 Capital Cube
Jun-21-17 04:26PM  [$$] Pharma recovers composure as price concerns ease Financial Times
03:00PM  Amgen An Undervalued Industry Leader Forbes
10:35AM  Amgen: In Defense of A Pipeline
08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Gilead Sciences and Sarepta Therapeutics Accesswire
Jun-20-17 03:42PM  Why This Billionaire Just Bought Gilead Sciences, Synergy, and Valeant Stock Motley Fool
02:55PM  Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada Zacks
09:43AM  Big Money Flowing Into Biotech Stocks - Again Forbes
09:06AM  Analyzing Eli Lillys Collaboration with KeyBioscience AG Market Realist
07:27AM  5 Most Profitable Big Pharma Stocks on the Market Right Now Motley Fool
Jun-19-17 03:23PM  ETFs with exposure to Gilead Sciences, Inc. : June 19, 2017 Capital Cube
12:45PM  These are the signals to watch out for before you buy or ... CNBC Videos
09:53AM  James Flynn Plays Two Key Biotech Stocks: Valeant Pharmaceuticals Intl Inc (VRX), Gilead Sciences, Inc. (GILD) SmarterAnalyst
05:59AM  Gilead Receives Approval in Canada for VEMLIDY (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection CNW Group
Jun-18-17 11:42AM  5 Answers to Questions Gilead Sciences' Investors Probably Have Motley Fool
Jun-16-17 02:44PM  3 Beaten-Down Stocks Ready to Bounce Back Motley Fool
01:14PM  Gilead Sciences, Inc. : GILD-US: Dividend Analysis : June 16th, 2017 (record date) : By the numbers : June 16, 2017 Capital Cube
09:35AM  Is Gilead Sciences a Great Stock for Value Investors? Zacks
Jun-15-17 04:21PM  New Data Shows TG Therapeutics Could Be Onto Something Big Motley Fool
03:20PM  Could This Small Biotech Pique Interest Of Gilead And Others? Investor's Business Daily
10:43AM  3 Stocks With Better Dividends Than CVS Health Corporation Motley Fool
Jun-14-17 11:49AM  Top 5 Biotech Stocks for 2017 Investopedia
09:34AM  Key Takeaways From William Blairs Annual Growth Stock Conference: Gilead Sciences, Inc. (GILD), Exelixis, Inc. (EXEL) SmarterAnalyst
Jun-13-17 05:43PM  3 Dividend Stocks to Buy on Sale Motley Fool
05:16PM  Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Gilead Sciences and Tesaro Accesswire
Jun-12-17 04:32PM  Are Sanofi, Gilead In A Bidding War Over This Small-Cap Biotech? Investor's Business Daily
12:40PM  Billionaire Israel Izzy Englander Bets on Three Biotech Stocks: Valeant Pharmaceuticals Intl Inc (VRX), Gilead Sciences, Inc. (GILD), Synergy Pharmaceuticals Inc (SGYP) SmarterAnalyst
09:40AM  Short Interest Surges in Major Biotechs 24/7 Wall St.
08:42AM  3 Beaten-Up Biotech Stocks: Are They Bargains? Motley Fool
08:15AM  Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment Business Wire
Jun-09-17 06:22PM  Why GlaxoSmithKline Stock Had a Breakout May Motley Fool
01:34PM  ETFs with exposure to Gilead Sciences, Inc. : June 9, 2017 Capital Cube
01:33PM  We Deliver: SBUX, AMGN, and more CNBC Videos
12:17PM  The 3 Best Value Stocks You Can Buy Right Now Motley Fool
08:03AM  Gilead Sciences, Inc.: The Bear Case From a Bull Motley Fool
Jun-08-17 02:41PM  The Best Hep C Drug Stock to Buy in 2017 Motley Fool
09:47AM  Gilead Sciences, Inc. :GILD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 8, 2017 Capital Cube
Jun-07-17 01:20PM  Spring Bank Pharmaceuticals' Hepatitis B Results in Context
Jun-06-17 04:26PM  3 Value Stocks Perfect for Retirement Motley Fool
07:24AM  Why Gilead Sciences Stock Slumped in May Motley Fool
Jun-04-17 02:22PM  3 Dividend Stocks for Daring Investors Motley Fool
07:42AM  3 Great Dividend Stocks to Buy That You Might Not Know Are Dividend Stocks Motley Fool
Jun-03-17 11:48AM  3 History-Making Stocks Motley Fool
Jun-02-17 06:55AM  Why Is Gilead Sciences (GILD) Down 3.5% Since the Last Earnings Report? Zacks
Jun-01-17 05:00PM  Gilead Sciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15 Business Wire
01:02PM  Gilead Sciences: Winning or Losing in HIV?
May-31-17 05:38PM  Gilead Single Tablet Regiment for HIV Good in Phase III Zacks
04:22PM  Better Buy: Biogen Inc. vs. Gilead Sciences Inc. Motley Fool
01:11PM  Gilead Keeps Muddying the M&A Waters Bloomberg
10:45AM  UPDATE: Gilead says four late-stage trials of HIV drug combination met primary endpoints MarketWatch
May-30-17 05:00PM  Gilead Sciences to Present at the 37th Annual William Blair Growth Stock Conference on Tuesday, June 13 Business Wire
04:21PM  Gilead's HIV Combo Passes Muster, But Can It Stand Up To Glaxo, Merck? Investor's Business Daily
02:36PM  Gilead Sciences CFO named Financial Woman of the Year American City Business Journals
10:02AM  Gilead Sciences: What's in the Pipeline?
09:37AM  Gilead's HIV drug meets goal in four late-stage studies Reuters
08:48AM  Gilead's HIV combination therapy succeeds in four late-stage studies Reuters
08:30AM  Gileads Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies Business Wire
07:37AM  What Analysts Recommend for Gilead Sciences in May 2017 Market Realist
May-29-17 10:37AM  Truvada Could Drive Gilead Sciences Revenue Growth Market Realist
09:07AM  Why Gileads HCV Franchise Could See a Decline in 2017 Market Realist
08:21AM  Meet the Cancer Therapy that Could Become the Second Best-Selling Drug in the World by Year's End Motley Fool
07:38AM  How Will Gilead Sciences Perform in 2017? Market Realist
May-28-17 07:04AM  7 Things You Didn't Know About Gilead Sciences, Inc. Motley Fool
May-27-17 08:00AM  Which Biotechs Benefit Most Under Trump's Tax Reform Vision? Investor's Business Daily
May-26-17 06:06PM  TAF-Based Regimens Could Boost Gilead Sciences Revenue Growth Market Realist
04:23PM  Genvoya Could Drive Gilead Sciences Revenue Growth in 2017 Market Realist
10:49AM  1 Underdog Stock I'm Watching Motley Fool
08:17AM  3 Value Stocks for Daring Investors Motley Fool
May-25-17 12:23PM  These 5 Healthcare Stocks Are Undervalued Forbes
09:50AM  Short Sellers Raise the Stakes in Major Biotechs 24/7 Wall St.
May-24-17 04:41PM  3 Reasons Gilead Sciences, Inc. Is a Better Dividend Stock Than Amgen, Inc. Motley Fool
02:29PM  Inovio Pharmaceuticals Stock Soars on Encouraging HIV Vaccine Readout Motley Fool
08:34AM  Is The Worst Behind Gilead Sciences? Motley Fool
May-23-17 02:06PM  Valeant and Gilead: Beaten Down Bargains or Truly Terrible? Motley Fool
May-22-17 02:30PM  Amgen's Woes: It Could Always Be Worse! Investopedia
May-19-17 06:46PM  Cramer's lightning round: I've got a message for the struggling Gilead Sciences CNBC
01:09PM  5 Reasons Big Biotech Could Gain 25%-30%
12:02PM  Why Stay Bullish On Gilead
09:06AM  Revisiting Bristol-Myers Squibbs Virology in 1Q17 Market Realist
May-18-17 07:37AM  A Doomed Trump Presidency Would Be a Terrifying Development for Pharmaceutical Stocks Motley Fool
May-17-17 03:42PM  3 Dividend Stocks You Haven't Thought Of Motley Fool
May-16-17 03:42PM  3 Best Dividend Stocks in Biotech Motley Fool
May-15-17 04:55PM  Gilead's last chronic HIV drug and what it plans to do now American City Business Journals
08:15AM  Blog Coverage: Ardelyx Reports Successful Trial Results for Treatment of Patients with Irritable Bowel Syndrome with Constipation Accesswire
May-14-17 09:03AM  Better Buy: Gilead Sciences, Inc. vs. Amgen Inc. Motley Fool
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise21.5873,3331,582,1593,273,302Jun 05 06:26 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale65.2473,3334,784,5313,199,969Jun 05 06:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJun 01Sale65.025,000325,114107,988Jun 05 06:15 PM
Cogan John FrancisDirectorMay 09Option Exercise20.7115,000310,57562,562May 11 06:14 PM
Cogan John FrancisDirectorMay 09Sale67.259,943668,66752,619May 11 06:14 PM
MARTIN JOHN CExecutive ChairmanMay 01Option Exercise21.5873,3331,582,1593,199,969May 03 05:42 PM
MARTIN JOHN CExecutive ChairmanMay 01Sale68.3173,3335,009,4293,126,636May 03 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMay 01Sale68.315,000341,529112,988May 03 05:41 PM
MARTIN JOHN CExecutive ChairmanApr 03Option Exercise21.5873,3331,582,1593,199,969Apr 05 05:29 PM
MARTIN JOHN CExecutive ChairmanApr 03Sale67.1873,3334,926,2873,126,636Apr 05 05:29 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMar 30Sale67.485,000337,392117,988Apr 03 06:23 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM
MADIGAN JOHN WDirectorNov 18Option Exercise20.71105,0002,174,025121,761Nov 22 02:45 PM
MADIGAN JOHN WDirectorNov 18Sale74.86105,0007,860,05916,761Nov 22 02:45 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 09Sale79.0010,000790,000122,964Nov 14 01:03 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise16.40100,0001,639,5003,231,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale73.76100,0007,376,0463,131,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanOct 03Option Exercise16.40100,0001,639,5003,231,096Oct 05 12:52 PM
MARTIN JOHN CExecutive ChairmanOct 03Sale77.63100,0007,762,9613,131,096Oct 05 12:52 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 22Sale81.845,000409,220132,964Sep 26 04:54 PM
MILLIGAN JOHN FPresident and CEOSep 06Option Exercise20.7470,0001,451,8001,128,963Sep 08 01:35 PM
MILLIGAN JOHN FPresident and CEOSep 06Sale77.7470,0005,442,0801,058,963Sep 08 01:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise16.40100,0001,639,5003,231,096Sep 06 02:40 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale77.48100,0007,748,3633,131,096Sep 06 02:40 PM
Lofton Kevin EDirectorAug 24Sale81.973,500286,8990Aug 25 05:05 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise39.132,00078,25564,305Aug 03 04:48 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise16.40100,0001,639,5004,119,727Aug 03 04:51 PM
MILLIGAN JOHN FPresident and CEOAug 01Option Exercise20.7470,0001,451,8001,128,963Aug 03 04:53 PM
MILLIGAN JOHN FPresident and CEOAug 01Sale70.9470,0004,965,5901,058,963Aug 03 04:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale80.50100,0008,049,7854,019,727Aug 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Sale79.812,000159,62062,305Aug 03 04:48 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500063,622Aug 02 04:43 PM
MILLIGAN JOHN FPresident and CEOJul 05Option Exercise16.40112,0001,836,2401,170,963Jul 07 02:50 PM
MILLIGAN JOHN FPresident and CEOJul 05Sale84.33112,0009,444,9211,058,963Jul 07 02:50 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise24.912,00049,81063,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Option Exercise16.40100,0001,639,5004,119,727Jul 06 01:28 PM
MARTIN JOHN CExecutive ChairmanJul 01Sale84.73100,0008,472,5234,019,727Jul 06 01:28 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale83.122,000166,25061,122Jul 06 01:26 PM